to Oslo Medtech
Register here to subscribe to our newsletter!
Oslo Medtech latest newsletter (May 2013)
Interested in previous newsletters? Click here
Generating innovation. For better living and health.
Medistim ASA, a Norwegian company that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the National Institute for Health and Clinical Excellence (NICE) today has accepted the health economics derived from routine usage of the VeriQ system for assessing graft blood flow during coronary artery bypass graft (CABG) surgery, compared to clinical assessment alone.
Written by Mark Gardner, DuVal & Partners on FDA.
CMS finally published a Proposed Rule for the Physician Payment Sunshine Act (the “Act”), which was passed last year. The Proposed Rule was initially due by October 1, a deadline CMS missed. All 121 pages of the Proposed Rule are located here: https://s3.amazonaws.com/public-inspection.federalregister.gov/2011-32244.pdf. We have attempted to break the Proposed Rule down to save you some time! Please call us if you need help preparing for the new law. Companies that fail to report are subject to fines ranging from $1000-10,000 per occurrence for unintentional conduct and $10,000-$100,000 for intentional conduct.
The EU Commissioner for Research and Innovation, Máire Geoghegan-Quinn, presents a short version of Horizon 2020 in this video.
In cooperation with HP, Leighton Contractors and a few others, IMATIShaswona majorPPP(Private – Public – Partership ) contract inAdelaide, Australia. The deliveryis based onImatis’deliveries ofDigitalHospitalsolutions, built forSt.Olav'sHospital andAHUS, wherethey havebeensubcontractedto Telenor.
“We will supply the new hospital’s Integraton Engine and mobile solutions, but have a number of options that could increase the delivery volume significantly”, says Morten Andresen in Imatis.
Oslo Medtech welcomes the Government's new national strategy for biotechnology, as Minister Tora Aasland presented on Friday 9 December, and will contribute actively to realize the biotechnology strategy!
It is very gratifying that the Government puts forward a strategy that will strengthen the application of research results in biotechnology and the development of businesses in this area, says Carl Christian Gilhuus-Moe, Chairman of Oslo Medtech.
A clinical trial at the Oslo University Hospital – Rikshospitalet, indicates that patients with intracranial aneurysm bleeds treated with Sensometrics Technology, were more than three times as likely to recover completely as compared to patients treated with traditional methods. Based on the findings, the hospital will integrate Sensometrics as its new, standard treatment method.
In the large evaluation of research in biology, medicine and health sciences conducted by the the Norwegian Research Council in 2011, many of the research groups scored very well. - It is particularly gratifying that Torbjørn Omland’s researchgroup (Cardiothoracic Research Group) got top marks, says research director Hilde Lurås. It shows that Ahus with a targeted effort may succeed to bring research at an international elite level.